Electric field therapy tested for tough lung cancer

NCT ID NCT06124118

Terminated Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This early-phase trial tests whether adding Tumor Treating Fields (TTFields) — a device that delivers electric fields to the tumor — to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 30 participants will receive the device alongside their usual treatment. The main goal is to check for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor Treating Fields (TTFields) device plus chemotherapy (carboplatin, paclitaxel) and immunotherapy (durvalumab)
What this could lead to: If successful, this could point toward a new combination therapy to better control advanced lung cancer.
What could go wrong: This is a very early Phase 1 safety trial with only 30 participants, so it may not show clear benefit. Adding TTFields to standard treatment could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.